Firstly, TCGA investigation revealed that PRAD had much more ASNS expression than normal tissue, and that ASNS was linked to worse BCRF survival in PRAD patients (Figure 9A, 9B). This evidence concerns the gene ASNS and prostate adenocarcinoma.